Our proprietary platform uses recently discovered induced pluripotent stem cells (iPSCs) which can for the first time create new cardiomyocytes, endothelial cells and smooth muscle cells with one master cell line that can also create an unlimited number of new cells to repair irreversibly damaged muscle/tissue. We have two stem cell therapeutics available to create new muscle in two difficult diseases.
ISX9-CPC combines the small molecule ISX-9 and human iPSCs to generate new cardiac tissue. Our preclinical studies have shown substantial improvement in cardiac function and significant reduction of scar tissue function following delivery of ISX9-CPC to damaged cardiac muscle.
GIVI-MPC uses the small molecule Givinostat to reprogram human iPSCs into new skeletal muscle tissue, enabling delivery of full-length dystrophin to DMD patients. Like heart disease, current drugs only deal with the symptoms and current gene therapy approaches for DMD only deliver a small portion of the dystrophin protein and thus cannot create any new muscle, offering insufficient clinical benefit.
Copyright © 2014 IPS HEART - All Rights Reserved.
Notice: Please ignore HR recruitment emails that are not from the domain "@ipsheart.com", they are not associated with IPS HEART.